ACADIA Pharmaceuticals - 53 Year Dividend History | ACAD

Historical dividend payout and yield for ACADIA Pharmaceuticals (ACAD) since 1971. The current TTM dividend payout for ACADIA Pharmaceuticals (ACAD) as of May 23, 2024 is $0.00. The current dividend yield for ACADIA Pharmaceuticals as of May 23, 2024 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.614B $0.726B
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company suffered a setback when the FDA issued a complete response letter to the supplemental new drug application for Nuplazid for treating dementia-related psychosis. Acadia resubmitted the supplemental new drug application to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. Notably, several additional studies on Nuplazid n targeting different CNS indications, such as?dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway.
Stock Name Country Market Cap PE Ratio